Evidence map›Paper›PMID 36934204›Full record

ArticleCommunications biology2023

Analysis of well-annotated next-generation sequencing data reveals increasing cases of SARS-CoV-2 reinfection with Omicron.

Scott Burkholz, Michael Rubsamen, Luke Blankenberg, Richard T Carback, Daria Mochly-Rosen, Paul E Harris

Open access · goldFull text read
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Omicron breakthrough infections in vaccinated or previously infected hamsters.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  9. Reinfection by SARS-CoV-2 by divergent Omicron sublineages, 16 days apart.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Scott Burkholz *Flow Pharma, Inc., Warrensville Heights, OH, USA.
Michael Rubsamen *Case Western Reserve University, Cleveland, OH, USA.
Luke BlankenbergTexas A&M University, College Station, TX, USA.
Richard T CarbackFlow Pharma, Inc., Warrensville Heights, OH, USA.
Daria Mochly-RosenStanford University School of Medicine, Department of Chemical and Systems Biology, Stanford, CA, USA.ORCID 0000-0002-6691-8733
Paul E HarrisFlow Pharma, Inc., Warrensville Heights, OH, USA. peh1@columbia.edu.
Flow Pharma (United States) · USCase Western Reserve University · USStanford University · USTexas A&M University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 has extensively mutated creating variants of concern (VOC) resulting in global infection surges. The Omicron VOC reinfects individuals exposed to earlier variants of SARS-CoV-2 at a higher frequency than previously seen for non-Omicron VOC. An analysis of the sub-lineages associated with an Omicron primary infection and Omicron reinfection reveals that the incidence of Omicron-Omicron reinfections is occurring over a shorter time interval than seen after a primary infection with a non-Omicron VOC. Our analysis suggests that a single infection from SARS-CoV-2 may not generate the protective immunity required to defend against reinfections from emerging Omicron lineages. This analysis was made possible by Next-generation sequencing (NGS) of a Danish cohort with clinical metadata on both infections occurring in the same individual. We suggest that the continuation of COVID-19 NGS and inclusion of clinical metadata is necessary to ensure effective surveillance of SARS-CoV-2 genomics, assist in treatment and vaccine development, and guide public health recommendations.

Indexed as

COVID-19SARS-CoV-2GenomicsHigh-Throughput Nucleotide SequencingHumansReinfection

Identifiers

PMID36934204
PMCPMC10024296
OpenAlexW4327857953

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read35
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.